IL33 and neoplasm: For instance, IL-33 release in murine HCC showed to markedly inhibit tumor growth via activated CD4+ and CD8+ T cells, in IL-33-expressing tumor-bearing mice, while IL-18/IL-12 cytokine therapy was effective in tumor regression prompted by induction of NK cells [178,179,180].